Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Tempest Therapeutics, Inc.

NASDAQ: TPST · Life Sciences · 12 alerts · CIK 1544227

Share price
$0.3418Close, Nov 16
Market cap
$6.83M
Shares outstanding
20MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tempest Therapeutics, Inc. filings on SEC EDGAR ↗

4:36 PM ET 8-K
Licensing Deal

Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.

Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.

Counterparty
Hebei Senlang Biotechnology Co., Ltd.

“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”

Matt Angel, Ph.D., President and Chief Executive Officer of Tempest

“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”

Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
6:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Tempest Therapeutics Nasdaq/NYSE Compliance Notice

Tempest Therapeutics received a deficiency notice from Nasdaq on November 4, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing of the company's common stock.

Counterparty
Nasdaq
Term
180 days
4:06 PM ET 8-K
Research Collaboration

Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M

Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.

Value
$5M
Counterparty
Factor Bioscience Inc.
Term
annual
5:06 PM ET 8-K
Research Collaboration

Tempest Therapeutics Research Collaboration with Heibei Senlang Biotechnology Co., Ltd.

Tempest Therapeutics entered into an exclusive collaboration and option agreement with Heibei Senlang Biotechnology to develop and commercialize an in vivo CAR-T technology platform worldwide, excluding Greater China. Tempest paid an option fee of approximately $0.447 million for a four-month window to license the technology, which includes a Phase 1 dual-targeting candidate for multiple myeloma. The deal establishes Tempest as a multi-platform in vivo CAR-T company, combining Senlang's lentiviral vector platform with Tempest's existing LNP delivery technology.

Counterparty
Heibei Senlang Biotechnology Co., Ltd.
Term
4 month option period
4:07 PM ET 8-K
Capital Raise

Tempest Therapeutics Capital Raise of $2.5M

Tempest Therapeutics entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and accompanying Series C and D warrants. The company raised approximately $2.5 million in gross proceeds, with the potential for an additional $5 million upon the cash exercise of the common warrants. Proceeds are intended for working capital and general corporate purposes.

Value
$2.5M
Counterparty
institutional investor

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.